Blissway vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Computer vision fleet safety platform with real-time driver behavior monitoring and in-cab coaching; YC W20-backed competing with Samsara and Lytx for fleet accident reduction and insurance cost savings.
About
Blissway is a Tel Aviv-based road safety technology company using computer vision and AI to monitor and analyze driver behavior in real-time — providing fleets, trucking companies, and insurance carriers with dashcam-based driver risk scoring, real-time coaching alerts, and safety analytics that reduce accident rates and insurance costs. Backed by Y Combinator (W20) with $2.63-9.3 million raised across multiple rounds including a 2023 round supported by Maniv Mobility, Measured Ventures, and others, Blissway operates in the fleet safety and telematics market.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.